Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23:9243-9249.

Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.

Benoist S, Brouquet A, Penna C, et al. Complete response of rectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24:3939-3945.

Berger AC, Sigurdson ER, LeVoyer T, et al. Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol. 2005;23:8706-8712.

Cassidy J, Clarke S, Rubio D, et al. First efficacy and safety results from XELOX-1/NO16966, a randomized 2x2 factorial phase III trial of XELOX vs. FOLFOX6 + bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC) [abstract]. Ann Oncol. 2006;17:(suppl 9). Abstract LBA3.

Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-766.

Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005;23:4866-4875.

Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.

De Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5-FU/LV in the adjuvant treatment of stage II and stage II colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol. 2005;23:16S. Abstract 3501.

Engstrom PF, Arnoletti JP, Benson AB 3rd, et al. Colon cancer. J Natl Compr Canc Netw. 2007; 5:884-925.

Engstrom PF, Arnoletti JP, Benson AB 3rd, et al. Rectal cancer. J Natl Compr Canc Netw. 2007; 5:940-81.

Engstrom PF, Arnoletti JP, Benson AB III, et al. The NCCN colon cancer clinical practice guidelines in oncology, version 1, 2008. Available at: http://www.nccn.org/professionals/physician_gls/default.asp. Accessed March 26, 2008.

Field MJ, Lohr, KN, eds. Clinical Practice Guidelines: Directions for a New Program. Washington DC: National Academy Press, 1990.

Fuchs CS, Marshall J, Mitchell EP, et al. Updated results of the BICC-C study comparing first-line irinotecan/fluoropyrimidine combinations +/- celecoxib in mCRC: Clinical data cut-off September 1, 2006 [abstract]. 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 276.

Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for Stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797-1806.

Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209-1214.

Gruenberger B, Scheithuaer W, Tamandl D, et al. Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with resectable colorectal cancer liver metastases [abstract]. J Clin Oncol. 2007;25(18S). Abstract 4060.

Hochster H, Hart LL, Ramanathan R, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE study [abstract]. J Clin Oncol. 2006;24(18S). Abstract 3510.

Hurwitz H, Fehrenbacher L, Novotny W. et al. Bevacizumab plus irinotecan, fluoruracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.

Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008;58:71-96.

Jonker DJ, O'Callaghan CJ, Karpetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl Med. 2007;357:2040-2048.

Joseph NE, Sigurdson ER, Hanlon AL, et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003;10:213-218.

Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colon cancer. J Clin Oncol. 2005;23:3706-3712.

Nordlinger B, van Cutsem E, Rougier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? Eur J Cancer. 2007;43:2037-2045.

Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715-722.

Peeters M, Van Cutsem E, Sienna S, et al. A phase 3 multicenter randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients with metastatic colorectal cancer [abstract]. American Association for Cancer Research 2006 Annual Meeting; April 1-5, 2006; Washington, DC. Abstract CP-1.

Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15:933-939.

Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol. 1998;25(Suppl 5):4-12.

Rothenberg ML, Blanke CD. Topoisomerase I inhibitors in treatment of colorectal cancer. Semin Oncol. 1999;26:632-639.

Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001;19:3801-3807.

Saltz L, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone in stage III colon cancer (Intergroup trial CALGB C89803) [abstract]. J Clin Oncol. 2004;22:14S. Abstract 3500.

Saltz LB, Clarke S, Diaz-Rubio E., et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC) [abstract]. 2007 Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract 238.

Saltz LB, Meropol NJ, Loehrer PJ, Sr., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-1208.

Sarli L, Bader G, Iusco D, et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer. 2005;41:272-279.

Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.

Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop- and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol. 2006;24:394-400.

Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212-2221.

Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer. 2006;6:202-207.